Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

Our stock screener has identified CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as a potential breakout candidate. This technical breakout setup pattern occurs when the stock consolidates after a strong uptrend. While the actual breakout is uncertain, it may be worth keeping an eye on NASDAQ:CPRX.

Technical analysis of NASDAQ:CPRX

ChartMill utilizes a proprietary algorithm to assign a Technical Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of technical indicators and properties.

We assign a technical rating of 7 out of 10 to CPRX. In the last year, CPRX was one of the better performers, but we do observe some doubts in the very recent evolution.

• The long term trend is positive and the short term trend is neutral. The long term trend may just continue or reversal may be around the corner!
• Looking at the yearly performance, CPRX did better than 83% of all other stocks.
• CPRX is part of the Biotechnology industry. There are 565 other stocks in this industry. CPRX outperforms 80% of them.
• CPRX is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so CPRX is lagging the market slightly.
• In the last month CPRX has a been trading in the 20.93 - 23.02 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Check the latest full technical report of CPRX for a complete technical analysis.

How does the Setup look for NASDAQ:CPRX

ChartMill incorporates a Setup Rating in its analysis, which measures the extent of consolidation in a stock over recent days and weeks. This rating, ranging from 0 to 10, is updated daily and takes into account multiple short-term technical indicators. The current setup rating for NASDAQ:CPRX is 9:

CPRX has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is very little resistance above the current price. There is a support zone below the current price at 21.79, a Stop Loss order could be placed below this zone. We notice that large players showed an interest for CPRX in the last couple of days, which is a good sign.

What matters for high growth investors.

• The recent financial report of CATALYST PHARMACEUTICALS INC demonstrates a 221.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• CATALYST PHARMACEUTICALS INC has achieved 25.33% growth in its revenue over the previous quarter, signaling positive momentum in its financial performance and potential market opportunities.
• Over the past 3 years, CATALYST PHARMACEUTICALS INC has demonstrated 25.48% growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• CATALYST PHARMACEUTICALS INC has achieved significant 1-year revenue growth of 85.9%, signaling its ability to capture market opportunities and drive top-line expansion. This growth indicates the company's effective execution and its potential for continued success.
• The recent financial report of CATALYST PHARMACEUTICALS INC demonstrates a 221.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• accelerating EPS growth for CATALYST PHARMACEUTICALS INC: the current Q2Q growth of 221.0% exceeds the previous year Q2Q growth of -245.0%.
• With positive growth in its free cash flow (FCF) over the past year, CATALYST PHARMACEUTICALS INC showcases its ability to generate strong cash flows and maintain a solid financial position. This growth reflects the company's efficient utilization of capital and its commitment to long-term value creation.
• The Return on Equity(ROE) of CATALYST PHARMACEUTICALS INC is 11.19%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
• CATALYST PHARMACEUTICALS INC exhibits a favorable Debt-to-Equity ratio at 0.0. This highlights the company's ability to limit excessive debt levels and maintain a strong equity base, demonstrating its financial stability and risk management practices.
• CATALYST PHARMACEUTICALS INC exhibits a favorable ownership structure, with an institutional shareholder ownership of 83.84%. This signifies a diverse investor base, which can contribute to a more stable and efficient market for the stock.
• With a track record of beating EPS estimates in the last 4 quarters, CATALYST PHARMACEUTICALS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• CATALYST PHARMACEUTICALS INC has achieved an impressive Relative Strength (RS) rating of 83.72, showcasing its ability to outperform the broader market. This strong performance positions CATALYST PHARMACEUTICALS INC as an attractive stock for potential price appreciation.

More ideas for high growth momentum breakouts can be found on ChartMill in our High Growth Momentum Breakout screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.